Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease

NCT04102579 is registered in ClinicalTrials.gov with Neurocrine Biosciences as lead sponsor.

NCT NCT04102579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04102579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease
Lead sponsor
Neurocrine Biosciences
Phase
Phase 3
Overall status
Completed
Start date
November 13, 2019
Completion date
October 26, 2021
Enrollment
128 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

chorea, huntington